309 related articles for article (PubMed ID: 28771058)
21. Genomics of myelodysplastic/myeloproliferative neoplasm.
Patwardhan PP; Aarabi M; Aggarwal N
Semin Diagn Pathol; 2023 May; 40(3):195-201. PubMed ID: 37105794
[TBL] [Abstract][Full Text] [Related]
22. Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes.
Kuykendall AT; Tokumori FC; Komrokji RS
Hematol Oncol Clin North Am; 2021 Apr; 35(2):337-352. PubMed ID: 33641873
[TBL] [Abstract][Full Text] [Related]
23. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D
Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478
[TBL] [Abstract][Full Text] [Related]
24. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract][Full Text] [Related]
25. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
Kuendgen A; Kasprzak A; Germing U
Front Oncol; 2021; 11():778741. PubMed ID: 34869027
[TBL] [Abstract][Full Text] [Related]
26. Advances in myelodysplastic/myeloproliferative neoplasms.
Prakash S; Arber DA; Bueso-Ramos C; Hasserjian RP; Orazi A
Virchows Arch; 2023 Jan; 482(1):69-83. PubMed ID: 36469102
[TBL] [Abstract][Full Text] [Related]
27. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
28. Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review.
Fontana D; Elli EM; Pagni F; Piazza R
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370785
[TBL] [Abstract][Full Text] [Related]
29. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
[TBL] [Abstract][Full Text] [Related]
30. Genetic mutations associated with blood count abnormalities in myeloid neoplasms.
Polprasert C; Kongkiatkamon S; Niparuck P; Rattanathammethee T; Wudhikarn K; Chuncharunee S; Kobbuaklee S; Suksusut A; Lanamtieng T; Lawasut P; Asawapanumas T; Bunworasate U; Rojnuckarin P
Hematology; 2022 Dec; 27(1):765-771. PubMed ID: 35766510
[TBL] [Abstract][Full Text] [Related]
31. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.
Mangaonkar AA; Lasho TL; Ketterling RP; Reichard KK; Gangat N; Al-Kali A; Begna KH; Pardanani A; Al Ali NH; Talati C; Sallman D; Padron E; Patnaik MM; Tefferi A; Komrokji R
Blood Cancer J; 2022 Feb; 12(2):26. PubMed ID: 35105856
[TBL] [Abstract][Full Text] [Related]
32. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
Faria C; Tzankov A
Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
[TBL] [Abstract][Full Text] [Related]
33. I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.
Gerds AT
Curr Hematol Malig Rep; 2014 Dec; 9(4):400-6. PubMed ID: 25195196
[TBL] [Abstract][Full Text] [Related]
34. [Genomic aberrations in myelodysplastic syndromes and related disorders].
Makishima H
Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
[TBL] [Abstract][Full Text] [Related]
35. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
Orazi A; Germing U
Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833
[TBL] [Abstract][Full Text] [Related]
36. Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO.
Kuykendall AT; Padron E
Curr Hematol Malig Rep; 2019 Dec; 14(6):543-549. PubMed ID: 31776774
[TBL] [Abstract][Full Text] [Related]
37. Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.
Karantanos T; Tsai HL; Gondek LP; DeZern AE; Ghiaur G; Dalton WB; Gojo I; Prince GT; Webster J; Ambinder A; Smith BD; Levis MJ; Varadhan R; Jones RJ; Jain T
Leuk Lymphoma; 2022 Aug; 63(8):1942-1948. PubMed ID: 35379077
[TBL] [Abstract][Full Text] [Related]
38. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Clara JA; Sallman DA; Padron E
Cancer Biol Med; 2016 Sep; 13(3):360-372. PubMed ID: 27807503
[TBL] [Abstract][Full Text] [Related]
39. Clinical analysis and literature review of a case with the myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Long B; Shi H; Zhu C
Hematology; 2020 Dec; 25(1):283-285. PubMed ID: 32657243
[No Abstract] [Full Text] [Related]
40. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]